Ensysce Biosciences (ENSC) Receivables - Net (2021 - 2025)
Ensysce Biosciences (ENSC) has disclosed Receivables - Net for 5 consecutive years, with $8.9 million as the latest value for Q3 2025.
- On a quarterly basis, Receivables - Net changed N/A to $8.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was $8.9 million, a N/A change, with the full-year FY2024 number at $1.6 million, down 85.05% from a year prior.
- Receivables - Net was $8.9 million for Q3 2025 at Ensysce Biosciences, down from $9.4 million in the prior quarter.
- In the past five years, Receivables - Net ranged from a high of $10.7 million in Q2 2022 to a low of $1.6 million in Q4 2024.
- A 5-year average of $6.3 million and a median of $8.9 million in 2025 define the central range for Receivables - Net.
- Peak YoY movement for Receivables - Net: plummeted 85.05% in 2024, then surged 394.74% in 2025.
- Ensysce Biosciences' Receivables - Net stood at $2.8 million in 2021, then surged by 282.14% to $10.7 million in 2022, then changed by 0.0% to $10.7 million in 2023, then tumbled by 85.05% to $1.6 million in 2024, then surged by 456.25% to $8.9 million in 2025.
- Per Business Quant, the three most recent readings for ENSC's Receivables - Net are $8.9 million (Q3 2025), $9.4 million (Q2 2025), and $9.2 million (Q1 2025).